Parkinson’s disease variant detection and disclosure: PD GENEration, a North American study
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Variants in seven genes (LRRK2, GBA1, PRKN, SNCA, PINK1, PARK7 and VPS35) have been formally adjudicated as causal contributors to Parkinson’s disease; however, individuals with Parkinson’s disease are often unaware of their genetic status since clinical testing is infrequently offered. As a result, genetic information is not incorporated into clinical care, and variant-targeted precision medicine trials struggle to enrol people with Parkinson’s disease. Understanding the yield of genetic testing using an established gene panel in a large, geographically diverse North American population would help patients, clinicians, clinical researchers, laboratories and insurers better understand the importance of genetics in approaching Parkinson’s disease. PD GENEration is an ongoing multi-centre, observational study (NCT04057794, NCT04994015) offering genetic testing with results disclosure and genetic counselling to those in the US (including Puerto Rico), Canada and the Dominican Republic, through local clinical sites or remotely through self-enrolment. DNA samples are analysed by next-generation sequencing including deletion/duplication analysis (Fulgent Genetics) with targeted testing of seven major Parkinson’s disease-related genes. Variants classified as pathogenic/likely pathogenic/risk variants are disclosed to all tested participants by either neurologists or genetic counsellors. Demographic and clinical features are collected at baseline visits. Between September 2019 and June 2023, the study enrolled 10 510 participants across >85 centres, with 8301 having received results. Participants were: 59% male; 86% White, 2% Asian, 4% Black/African American, 9% Hispanic/Latino; mean age 67.4 ± 10.8 years. Reportable genetic variants were observed in 13% of all participants, including 18% of participants with one or more ‘high risk factors’ for a genetic aetiology: early onset (<50 years), high-risk ancestry (Ashkenazi Jewish/Basque/North African Berber), an affected first-degree relative; and, importantly, in 9.1% of people with none of these risk factors. Reportable variants in GBA1 were identified in 7.7% of all participants; 2.4% in LRRK2; 2.1% in PRKN; 0.1% in SNCA; and 0.2% in PINK1, PARK7 or VPS35 combined. Variants in more than one of the seven genes were identified in 0.4% of participants. Approximately 13% of study participants had a reportable genetic variant, with a 9% yield in people with no high-risk factors. This supports the promotion of universal access to genetic testing for Parkinson’s disease, as well as therapeutic trials for GBA1 and LRRK2-related Parkinson’s disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite most cases of PD resulting from sporadic mutations, inherited PD remains a legitimate concern and is highly correlated with many genes, including Synuclein alpha (SNCA), Leucine-rich Repeat Kinase 2 (LRRK2), Parkin (PRKN), PTEN Induced Kinase 1 (PINK1), VPS35 Retromer Complex Component (VPS35), and Vacuolar Protein Sorting 13 Homolog C (VPS13C) [137].”
From The Impact of Neurotoxin Proteins Trafficked by Primary Cilia and Extracellular Vesicles in Neurodegenerative Diseases (2025) · cites this paper as [137]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W. W., Hegde, M., Lyon, E., Spector, E., et al. (2015) · Genetics in Medicine · doi:10.1038/gim.2015.30 · Cited by 32,594
MDS clinical diagnostic criteria for Parkinson’s disease
Postuma, R. B., Berg, D., Stern, M., Poewe, W., Olanow, C. W., Oertel, W., Obeso, J., Marek, K., Litvan, I., Lang, A. E., et al. (2015) · Movement Disorders · doi:10.1002/mds.26424 · Cited by 7,653
Self-citationEpidemiology of Parkinson's disease
de Lau, L. M., & Breteler, M. M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70471-9 · Cited by 4,110
Bloem, B. R., Okun, M. S., & Klein, C. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00218-x · Cited by 3,920
Nalls, M. A., Blauwendraat, C., Vallerga, C. L., Heilbron, K., Bandres-Ciga, S., Chang, D., Tan, M., Kia, D. A., Noyce, A. J., Xue, A., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30320-5 · Cited by 2,454
Self-citationParkinson's disease: from monogenic forms to genetic susceptibility factors
Lesage, S., & Brice, A. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp012 · Cited by 945
Strande, N. T., Riggs, E. R., Buchanan, A. H., Ceyhan-Birsoy, O., DiStefano, M., Dwight, S. S., Goldstein, J., Ghosh, R., Seifert, B. A., Sneddon, T. P., et al. (2017) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2017.04.015 · Cited by 567
Duran, R., Mencacci, N. E., Angeli, A. V., Shoai, M., Deas, E., Houlden, H., Mehta, A., Hughes, D., Cox, T. M., Deegan, P., et al. (2013) · Movement Disorders · doi:10.1002/mds.25248 · Cited by 146
Self-citationAlcalay, R. N., Caccappolo, E., Mejia-Santana, H., Tang, M. X., Rosado, L., Ross, B. M., Verbitsky, M., Kisselev, S., Louis, E. D., Comella, C., et al. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.194 · Cited by 145
Self-citationFeatures of GBA-associated Parkinson’s disease at presentation in the UK Tracking Parkinson’s study
Malek, N., Weil, R. S., Bresner, C., Lawton, M. A., Grosset, K. A., Tan, M., Bajaj, N., Barker, R. A., Burn, D. J., Foltynie, T., et al. (2018) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-317348 · Cited by 133
Cited by
Uncovering the genetic basis of Parkinson's disease globally: from discoveries to the clinic
Lim, S., Tan, A. H., Ahmad‐Annuar, A., Okubadejo, N. U., Lohmann, K., Morris, H. R., Toh, T. S., Tay, Y. W., Lange, L. M., Bandrés‐Ciga, S., et al. (2024) · The Lancet Neurology · doi:10.1016/s1474-4422(24)00378-8 · Cited by 98
“The yield also depends on the number of genes tested, 10 for example whether focusing on established PD-linked genes 12,50 or screening a larger neurodegenerative panel with 50 genes.”
Self-citationDorsey, E. R., Miranda, B. R. D., Hussain, S., Bloem, B. R., Elbaz, A., Llibre‐Guerra, J. J., Lo, R. Y., Goldman, S. M., & Tanner, C. M. (2025) · The Lancet Neurology · doi:10.1016/s1474-4422(25)00287-x · Cited by 56
Updated MDSGene review on the clinical and genetic spectrum of LRRK2 variants in Parkinson´s disease
Krüger, C., Lim, S., Buhrmann, A., Fahrig, F. L., Gabbert, C., Bahr, N., Madoev, H., Marras, C., Klein, C., & Lohmann, K. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-00881-9 · Cited by 52
Self-citationClassification and Genotype–Phenotype Relationships of GBA1 Variants: MDSGene Systematic Review
Rossi, M., Schaake, S., Usnich, T., Boehm, J., Steffen, N., Schell, N., Krüger, C., Gül, T., Bahr, N., Kleinz, T., et al. (2025) · Movement Disorders · doi:10.1002/mds.30141 · Cited by 41
“6,42 43-46 An earlier age of disease onset than sporadic PD has been reported in GBA1 -related PD. 5,47,48 Data from the Rostock Parkinson ’ s disease observational clinical study aiming to determine the frequency and spectrum of genetic variants contributing to PD in a large international cohort…”
Self-citationGenetics of Parkinson's Disease: From Causes to Treatment
Westenberger, A., Brüggemann, N., & Klein, C. (2024) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041774 · Cited by 42
A Global Perspective of GBA1-Related Parkinson’s Disease: A Narrative Review
Koros, C., Bougea, A. M., Alefanti, I., Simitsi, A., Papagiannakis, N., Pachi, I., Sfikas, E., Antonelou, R. C., & Stefanis, L. (2024) · Genes · doi:10.3390/genes15121605 · Cited by 30
Potential common pathogenesis of several neurodegenerative diseases
Fan, T., Peng, J., Liang, H., Chen, W., Wang, J., & Xu, R. (2025) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-01054 · Cited by 31
Parkinson Disease and the Gut: A Primer for Gastroenterologists
Sharma, A., Voigt, R. M., Goetz, C. G., & Keshavarzian, A. (2025) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003508 · Cited by 19
Clinical and functional evidence for the pathogenicity of the LRRK2 p.Arg1067Gln variant
Lim, S., Toh, T. S., Hor, J. W., Lim, J. L., Lit, L. C., Ahmad‐Annuar, A., Tay, Y. W., Foo, J. N., Ng, E. Y., Muthusamy, K. A., et al. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-00884-6 · Cited by 15
Self-citationGlobal Perspectives on Returning Genetic Research Results in Parkinson Disease
Tan, A. H., Awad, P. S., Schuh, A. F. S., Lim, S., Madoev, H., Ahmad‐Annuar, A., Solle, J. C., Wegel, C., Doquenia, M. L. M., Dey, S., et al. (2024) · Neurology Genetics · doi:10.1212/nxg.0000000000200213 · Cited by 16
“22 While the GP2 is a genetic discovery initiative and not an e ff ort primarily aiming to return genetic results to individual patients, we have also begun to navigate and support RoR by partnering with PDGENEration, 40 an initiative designed to carefully return genetic results to patients.”
Self-citationClinical genetic testing in Parkinson’s disease should become part of routine patient care
Gan‐Or, Z. (2024) · Brain · doi:10.1093/brain/awae181 · Cited by 13
Yin, E. P., & Dieriks, B. V. (2025) · Journal of Parkinson s Disease · doi:10.1177/1877718x241304814 · Cited by 18
“134,135 A recent large multi-center study advocating for better genetic testing reported low numbers of PINK1 PD but acknowledged that their cohort was predominantly European, 136 which shows that this lack of ethnic diversity is still a current issue requiring active and intentional attention.”
Emborg, M. E., Metzger, J. M., D’Amour, K. A., Colwell, J. C., Neumann, L., Zhang, A., & Federoff, H. J. (2025) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2025.111297 · Cited by 11
“Herein, we discuss how the host ’ s immune system differentially affects the graft depending on the origin of the cells and reflect on the advantages and limitations of the immune paradigms utilized to assess graft-related outcomes.”
Neilson, L. E., Khattab, Y. I., & Lim, M. M. (2025) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-025-01452-4 · Cited by 16
LRRK2 as a Potential Disease‐Modifying Target in Sporadic Parkinson's Disease
Lang, A. E., Hauser, R. A., Kalia, L. V., Hersh, B. P., Berger, Z., Arenas, R. L., Paisán‐Ruiz, C., Fraser, K. B., Jennings, D. L., Kluss, J. H., et al. (2025) · Movement Disorders · doi:10.1002/mds.70100 · Cited by 13
Brooker, S. M., Pasquini, J., Choi, S. H., Lafontant, D.-E., Fereshtehnejad, S., Zeighami, Y., Grillo, P., Riboldi, G. M., Azizi, H., Moqadam, R., et al. (2026) · Movement Disorders · doi:10.1002/mds.70197 · Cited by 15
Self-citationLüth, T., Caliebe, A., Gabbert, C., Sendel, S., Laabs, B., König, I. R., Klein, C., & Trinh, J. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-01010-2 · Cited by 13
“Among the ~15% of PD patients where the disorder is explained by a single pathogenic variant (i.e., monogenic PD) or strong risk factor 3,4 , the LRRK2 G2019S variantisthemostfrequentcauseofautosomal-dominantPD( LRRK2 -PD).”
Akçimen, F., Paquette, K., Crea, P. W., Step, K., Waldo, E., Koretsky, M. J., Awad, P. S., Achoru, C., Taiwo, F., Ozomma, S. I., et al. (2025) · Brain · doi:10.1093/brain/awaf379 · Cited by 11
Blauwendraat, C., Noyce, A. J., Mata, I. F., Screven, L. A., Solle, J. C., Dumanis, S. B., Riley, E. A. U., Periñán, M. T., Okubadejo, N. U., Klein, C., et al. (2025) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2025.07.014 · Cited by 12
“30 36 In addition to these 7 genes, there are >10 genes re-ported to contain pathogenic variants that cause PD.”
Self-citationA PLAN to address the Parkinson pandemic
Dorsey, E. R., Okun, M. S., & Bloem, B. R. (2025) · Journal of Parkinson s Disease · doi:10.1177/1877718x251378115 · Cited by 14
“25,26 These advances have enhanced our understanding of its pathophysiology, including Parkinson ’ s characteristic mitochondrial and lysosomal dysfunction, enabled genetic testing, and spurred the development of gene-directed therapies.”
The genetics of autosomal recessive early-onset Parkinson's disease
Cogan, G., Lesage, S., & Brice, A. (2025) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2025.103141 · Cited by 10
Flores‐Ocampo, V., Lim, W. Y., Ogonowski, N. S., García‐Marín, L. M., Ong, J., Yeow, D., Gonzaga-Jauregui, C. G., Kumar, K. R., & Rentería, M. E. (2025) · Genes · doi:10.3390/genes16040454 · Cited by 9
Pokotylo, M. M., Brüggemann, N., & Prasuhn, J. (2025) · Aging and Disease · doi:10.14336/ad.2025.0619 · Cited by 14
“Around 15% of PD cases are attributed to a known genetic cause related to the strong genetic risk factor GBA1 (~10%), or pathogenic mutations in SNCA, LRRK2, PRKN, PARK7 (DJ-1), PINK1, and some more rare genes while 85% remain without a known underlying monogenic cause [3,4].”
A multi-dimensional view on the etiology of Parkinson’s disease
Bernhardt, R., & Schulze-Hentrich, J. M. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-01150-5 · Cited by 10
“…when considering patients with a familial form of PD caused by mutation in one of the 7 well established PD genes ( SNCA , LRRK2 , GBA1 , PRKN , PINK1 , PARK7 and VPS35 ) 7 , the penetrance of the disease is not always high and varies strongly across different populations and ethnicities 8 .”
Interplay of GBA1 with lysosomal dysfunction and inflammation in Parkinson’s disease
Wang, R., Hatano, T., Hattori, N., & Cossu, D. (2025) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-25-01082 · Cited by 11
Matarazzo, M., Borghammer, P., Elsayed, I. T., Goldman, J. G., Huang, Y., Lohmann, K., Svenningsson, P., Kalia, L. V., Berg, D., & Kordower, J. H. (2026) · Movement Disorders · doi:10.1002/mds.70324 · Cited by 12
“Monogenic causes of PD, that is, pathogenic and coding risk variants in genes such as LRRK2, SNCA, PRKN, PINK1 , and GBA1 , are present in approximately 4% to 20% of PD patients, 122,123 especially in patients with early-onset disease.”
Self-citationLange, L. M., Fang, Z., Makarious, M. B., Kuznetsov, N., Brolin, K. A., Ballard, S., Bardien, S., Doquenia, M. L. M., Heutink, P., Houlden, H., et al. (2026) · The Lancet Neurology · doi:10.1016/s1474-4422(26)00198-5 · Cited by 21
Lange, L. M., Fang, Z., Makarious, M. B., Kuznetsov, N., Brolin, K. A., Ballard, S. L., Bardien, S., Doquenia, M. L. M., Heutink, P., Houlden, H., et al. (2025) · medRxiv · doi:10.1101/2025.07.08.25330815 · Cited by 8
“We used clinical exome sequencing data from 10,454 individuals with PD generated by PDGENEration 10 and released as part of GP2 Data Release 8 (DOI 10.5281/zenodo.13755496) 11 .”
InfluentialSelf-citationKleinz, T., Cavallieri, F., Borsche, M., Toschi, G., Valzania, F., Fioravanti, V., Valente, E. M., Mitrotti, P., Avenali, M., Zittel, S., et al. (2025) · Movement Disorders · doi:10.1002/mds.70037 · Cited by 9
Self-citationEarly-Onset Parkinson’s Disease: Unique Features and Management Approaches
Hickman, J. L., Tsai, A., Fullard, M. E., Korsmo, M., Forbes, E., Aslam, S., Baumgartner, A. J., Feuerstein, J., & Bayram, E. (2025) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-025-01470-2 · Cited by 9
“In the North American PDGENEration cohort, report - able variants were identified in 18.4% of people with EOPD; notably higher than the overall cohort with reportable vari - ants identified in 12.9% across all participants [ 33 ].”
InfluentialThe potential of distributed diagnostics for the early detection of Parkinson's disease
Khanna, A., Beck, J. C., Poston, K. L., Schwarzschild, M. A., & Jones, G. B. (2025) · Journal of Parkinson s Disease · doi:10.1177/1877718x251336118 · Cited by 6
“7 The use of these molecular diagnostics coupled with genetic diagnostics that can identify heritable forms of the disease, 8 is largely limited to specialty PD care currently while their availability, cost, invasiveness, and therapeutic applications evolve.”
Self-citationTwo lysosomal genes ATP13A2 and GBA1 interact to drive neurodegeneration
Gu, M., Zhao, J., Deng, M., Lin, G., Pan, X., Lin, W. W., Ma, M., Kim, J., Byeon, S. K., Pandey, A., et al. (2026) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00923-z · Cited by 7
“In contrast, heterozygous GBA1 variants do not cause GD, yet they are the most common genetic risk factors for PD, present in 7–15% of individuals with PD and conferring a fivefold increased risk on average [16, 20, 21].”
Anis, S., Weill, C., Ponger, P., Nassar, M., Reiner, J., Chorin, O., Parlar, S. C., Alcalay, R. N., Gan‐Or, Z., Ezra, A., et al. (2025) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2025.107940 · Cited by 6
Self-citationKals, M., Reigo, A., Teder‐Laving, M., Vaht, M., Nikopensius, T., Metspalu, A., & Toomsoo, T. (2025) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.70011 · Cited by 5
The LRRK2 p.L1795F variant causes Parkinson’s disease in the European population
Lange, L. M., Levine, K. S., Fox, S. H., Marras, C., Ahmed, N., Kuznetsov, N., Vitale, D., Iwaki, H., Lohmann, K., Marsili, L., et al. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-00896-2 · Cited by 5
“Pathogenicvariantsinthe LRRK2 geneareamongthemostcommoncauses of autosomal dominant Parkinson ’ s disease (PD) 1,2 and are thought to act through a gain-of-function mechanism that increases kinase activity 3 .”
Self-citationBarriers to clinical genetic testing in movement disorders
Yeow, D., Rudaks, L. I., & Kumar, K. R. (2025) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001381 · Cited by 5
“…testing is constantly growing and there is a need for updated clinical guidelines to better and PD GENEration studies identified a reportable genetic variant in up to 15% of all PD patients [2 && ,3 && ], sparking calls to consider genetic testing as routine care for all patients with PD [4].”
Gerard, J. P., Tan, A. H., Lim, S., Ahmad‐Annuar, A., Schee, J. P., & Gopalan, N. (2025) · Journal of Genetic Counseling · doi:10.1002/jgc4.70069 · Cited by 4
Chiang, C. Y., Pratuseviciute, N., Lin, Y., Adhikari, A., Yeshaw, W. M., Flitton, C., Sherpa, P., Tonelli, F., Rektorová, I., Lynch, T., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116031 · Cited by 9
Hach, A., Lohmann, K., Funayama, M., Menon, P. J., Vollstedt, E., Kleinz, T., Yoshino, H., Lesage, S., Meier, B., Sue, C. M., et al. (2026) · Annals of Neurology · doi:10.1002/ana.78180 · Cited by 6
Self-citationLa maladie de Parkinson : de la génétique aux thérapies ciblées
Cogan, G., & Brice, A. (2025) · Comptes Rendus Biologies · doi:10.5802/crbiol.174 · Cited by 4
PTEN: a new dawn in Parkinson’s disease treatment
Yang, X., Liu, T., & Cheng, H. (2025) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2025.1497555 · Cited by 4
A Novel α‐Synuclein K58N Missense Variant in a Patient with Parkinson's Disease
Al‐Azzani, M., Weber, S., Ramalingam, N., Ramón, M., Shvachiy, L., Mestre, G., Zech, M., Sicking, K., de Opakua, A. I., Jayanthi, V., et al. (2025) · Movement Disorders · doi:10.1002/mds.70030 · Cited by 7
“14,15 These aSyn variants include p.G14R, p.V15A, p.A30G, p.A30P, p.E46K, p.H50Q, p.G51D, p.A53T, p.A53E, p.A53V, and p.T72M, highlighting aSyn ’ s central role in PD. 3,6,16-24 However, pathogenic SNCA variants are extremely rare, accounting for only 0.1% to 0.2% of cases.”
InfluentialCogan, G., Tesson, C., Welment, L., Clot, F., Leguern, É., Lanore, A., Dürr, A., Cormier‐Dequaire, F., Debilly, B., Planes, M., et al. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-01141-6 · Cited by 3
The genetic architecture of Parkinson’s disease on the Island of Crete
Boura, I., Sait, S., Marinakis, N. M., Kumar, A., Chia, R., Ray, A., Vatsellas, G., Loupis, T., Pavlaki, V., Makrythanasis, P., et al. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-01192-9 · Cited by 2
“The suboptimal results of such initiatives, including ongoing trials on GBA1 - or LRRK2 -PD 6,7 , have been largely attributed to low enrollment of genetically characterized PD patients 8 .”
Genetic Testing by Age at Onset in Parkinson Disease
Balck, A., Vollstedt, E., Westenberger, A., Lange, L. M., Trinh, J., Kasten, M., Lohmann, K., Brüggemann, N., Trenkwalder, C., Mollenhauer, B., et al. (2026) · JAMA Neurology · doi:10.1001/jamaneurol.2026.1112 · Cited by 5
Self-citationKukreja, V., Ahuja, V., Ati, M., Hariharan, S., Krishnamoorthy, M., Sharma, R., & Bhattacherjee, A. (2025) · Results in Engineering · doi:10.1016/j.rineng.2025.105317 · Cited by 3
PRKN/PINK1 Mutations in a Chinese Patient With Early‐Onset Parkinson's Disease
Lu, Z., Sun, Y., Guo, L., Xin, M., Du, Y., Dai, R., Chen, G., Wang, H., & Wang, G. (2025) · Brain and Behavior · doi:10.1002/brb3.70822 · Cited by 2
“An earlier age at onset (AAO), a positive family history, and/or a specific heritage are all likely indicators of positive gene variations (Cook et al. 2024).”
A novel alpha-synuclein K58N missense variant in a patient with Parkinson’s diseasePreprint
Al‐Azzani, M., Weber, S., Ramalingam, N., Ramón, M., Shvachiy, L., Mestre, G., Zech, M., Sicking, K., de Opakua, A. I., Jayanthi, V., et al. (2025) · medRxiv · doi:10.1101/2025.02.07.25321793 · Cited by 3
Danna, R., Kondle, S., Amar, O., Mabourakh, M., Chen, G., Fadol, W. B., & Mohieldin, A. M. (2025) · Biology · doi:10.3390/biology14121787 · Cited by 2
“…PD remains a legitimate concern and is highly correlated with many genes, including Synuclein alpha (SNCA), Leucine-rich Repeat Kinase 2 (LRRK2), Parkin (PRKN), PTEN Induced Kinase 1 (PINK1), VPS35 Retromer Complex Component (VPS35), and Vacuolar Protein Sorting 13 Homolog C (VPS13C) [137].”
Synergistic blood-based diagnostic value of AP3B1 and BMPR2 in Parkinson’s disease
Zhao, X., Li, Y., Luan, Y., Ding, T., Yang, X., Geng, X., Zhang, T., Pan, J., Xiao, Z., Pan, W., et al. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-01134-5 · Cited by 3
“Speci fi cally, exosome-based assays often suffer from low RNA yield and poor scalability, limiting their clinical utility 39 – 42 .”
Parkinson's disease in transition: Genetics, biomarkers, and emerging therapeutics
Fan, S., Okuzumi, A., Chen, P., Tai, Y., Kuo, Y.-C. J., Tai, C., Li, C., Chiang, H., Hatano, T., & Lin, C. (2025) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2025.12.005 · Cited by 3
Malik, M., Brüggemann, N., Usnich, T., Borsche, M., Demetrowitsch, T. J., Laabs, B., Schwarz, K., Bauer, P., Lohmann, K., Klein, C., et al. (2026) · npj Parkinson s Disease · doi:10.1038/s41531-025-01255-x · Cited by 4
Self-citationPlasma Glucosylsphingosine in GBA1 E365K , N409S, and L483P Heterozygous Mutation Carriers
Agin‐Liebes, J., Haimovich, A., Griep, R., Hatcher, N. G., Yao, L., Waters, C., Padmanabhan, S., & Alcalay, R. N. (2026) · Movement Disorders · doi:10.1002/mds.70205 · Cited by 2
Self-citationMerchak, A. R., Herrick, M. K., Houser, M. C., Keating, C. E., Chang, J., & Tansey, M. G. (2026) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2026.1794784 · Cited by 2
The Global Parkinson's Disease Genetics ( GP2 ) Genome Browser
Fang, Z., Grant, R. H., Vitale, D., Hernández, C. F., Hong, S., Leonard, H. L., Makarious, M. B., Lange, L. M., Solomonson, M., Heutink, P., et al. (2026) · Movement Disorders · doi:10.1002/mds.70309 · Cited by 4
Self-citationStevens, E., Ghilardi, M. F., Rocco, A. D., Lima, M. A. C., Tatti, E., Sperlakis, D., Fearday, J., Deoudes, M.-M., Vanegas‐Arroyave, N., Hernandez, D., et al. (2025) · medRxiv · doi:10.1101/2025.05.02.25326745 · Cited by 2
Self-citationHadad, R., Alcalay, R. N., Senderova, I., Nassar, M., Milicic, A., Aharon‐Peretz, J., Allen, I. E., Ben‐Hayun, R., Chasnyk, N., Morani, I., et al. (2025) · Journal of Parkinson s Disease · doi:10.1177/1877718x251354986 · Cited by 1
Self-citationWES-Based Screening of a Swedish Patient Series with Parkinson’s Disease
Kafantari, E., Brolin, K. A., Wallenius, J., Swanberg, M., & Puschmann, A. (2025) · Genes · doi:10.3390/genes16121482 · Cited by 6
“%) carriers of LRRK2 variants, mostly p.(Gly2019Ser) [36].”
Chen, S., Yang, N., Liu, J., Xu, S., Xu, S., Wang, J., Li, C., & Liu, Y.-M. (2026) · BMC Neurology · doi:10.1186/s12883-025-04593-8 · Cited by 1
“Among them, the positive rate of EOPD was 19.9% [4, 5].”
InfluentialGenetic and Pathological Testing Attitudes for Parkinson's Disease in At‐Risk Relatives
Weil, T., Mirelman, A., Alcalay, R. N., Omer, N., Ponger, P., & Thaler, A. (2026) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.70535 · Cited by 1
“29,30”
Self-citationWang, J., Ibrahim, V., Agin‐Liebes, J., NANCE, M. A., Caulfield, M., Naito, A., Galvelis, K. G., Beck, J. C., Alcalay, R. N., & Wills, A.-M. A. (2026) · Genetics in Medicine Open · doi:10.1016/j.gimo.2026.104391 · Cited by 1
“In the 5 years since the launch of PD GENEration, over 25,000 individuals with Parkinson disease have enrolled in the study through referral by clinicians, referral by clinical trial sites participating in PD GENEration, and through online self-referral supported via online advertising and social…”
Self-citationLRRK2 and GBA1 in Lewy body diseases: neuropathological subtypes at opposite ends of a spectrum?
Jha, V., & Kalia, L. V. (2026) · Molecular Neurodegeneration · doi:10.1186/s13024-026-00939-z · Cited by 1
“GBA1 variants are found in approximately 7% to 12% of PD patients in European ancestry cohorts [19, 20].”
Return of genetic results to persons with Parkinson's disease: Blessing or foe?
Shiner, T., & Alcalay, R. N. (2026) · Journal of Parkinson s Disease · doi:10.1177/1877718x261470605 · Cited by 1
“23 Similarly, the ROPAD study reported pathogenic variants in approximately 15% of tested individuals across multiple countries.”
Self-citationPD GENEration: an international Parkinson’s disease genetic research study
Galvelis, K. G., Dilliott, A. A., Dini, M., León, R. D., Thom, M., Azcárate, I., Bothwick, N., Caboy, L., Coral-Zambrano, A., Doshier, K., et al. (2026) · BMC Neurology · doi:10.1186/s12883-026-05426-y · Cited by 1
Self-citationLysosomal dysfunction in neurodegenerative disease
Brooker, S. M., Coukos, R., & Krainc, D. (2026) · Nature Reviews Neurology · doi:10.1038/s41582-026-01262-3 · Cited by 2
“LRRK2 gene variants are the most common genetic cause of familial PD and also represent a frequent genetic aetiology for sporadic PD 17,58 .”
Genetic-based diagnostics of Parkinson’s disease and other Parkinsonian syndromes
Somerville, E. N., & Gan‐Or, Z. (2024) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2024.2427625 · Cited by 3
“The Rostock Parkinson’s Disease (ROPAD) [177] and PD GENEration [178] studies are both multi-centered studies that aimed to test the feasibility and yield of genetic testing for PD risk variants in large populations, with some notable variability in methodologies (Table 2).”
Precision medicine and music therapy for Parkinson’s Disease
Li-Hua, P., Jallow, L., Tan, Y., & Bajinka, O. (2025) · Clinical Parkinsonism & Related Disorders · doi:10.1016/j.prdoa.2025.100382 · Cited by 1
“Recent breakthroughs in genetic testing have identified clinically actionable mutations in genes such as LRRK2 and GBA1 , which are present in approximately 13 % of PD patients and enable targeted therapeutic interventions [1].”
MDSGene update and expansion: Clinical and genetic spectrum of LRRK2 variants in Parkinson’s diseasePreprint
Krüger, C., Lim, S., Buhrmann, A., Fahrig, F. L., Gabbert, C., Bahr, N., Madoev, H., Marras, C., Klein, C., & Lohmann, K. (2024) · medRxiv · doi:10.1101/2024.12.10.24318787 · Cited by 1
Self-citationMalik, M., Brüggemann, N., Usnich, T., Borsche, M., Demetrowitsch, T. J., Schwarz, K., Bauer, P. O., Lohmann, K., Klein, C., & Kunze, T. (2025) · medRxiv · doi:10.1101/2025.04.17.25326025 · Cited by 1
Self-citationBrooker, S. M., Pasquini, J., Choi, S. H., Lafontant, D.-E., Fereshtehnejad, S., Zeighami, Y., Grillo, P., Riboldi, G. M., Azizi, H., Moqadam, R., et al. (2025) · medRxiv · doi:10.1101/2025.10.01.25337085 · Cited by 1
Self-citationAslanzadeh, V., Glendinning, S., Sari, Y., Clarke, M., Rodger, C. J., Lin, X., Lenka, D. R., Richardson, L., Liang, J. R., Kleinz, T., et al. (2026) · doi:10.64898/2026.02.09.704817 · Cited by 1
Self-citationLüth, T., Caliebe, A., Gabbert, C., Sendel, S., Laabs, B., König, I. R., Klein, C., & Trinh, J. (2024) · medRxiv · doi:10.1101/2024.09.06.24313168
Genetic Variants for Parkinson's Disease Are More Common Than Previously Thought
Talan, J. (2024) · Neurology Today · doi:10.1097/01.nt.0001069136.35333.30
Sendel, S., Landoulsi, Z., Lohmann, K., Laabs, B., Kasten, M., Vollstedt, E., Usnich, T., Balck, A., Berg, D., Bobbili, D. R., et al. (2026) · npj Parkinson s Disease · doi:10.1101/2025.02.28.25323076
Self-citationTropea, T. F., Anis, S., & Ramirez‐Zamora, A. (2025) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2025.107810
Self-citationHach, A., Lohmann, K., Funayama, M., Menon, P. J., Vollstedt, E., Kleinz, T., Yoshino, H., Lesage, S., Meier, B., Sue, C. M., et al. (2025) · medRxiv · doi:10.1101/2025.05.07.25326886
Self-citationHoyt, A., Dorney, C., Auinger, P., Murphy, K., Porto, M., Schmier, K., Wilson, R. M., Beck, J. C., Benvengo, S., Biglan, K., et al. (2025) · JMIR Research Protocols · doi:10.2196/71955 · Cited by 1
“In December 2024, because of concerns regarding our ability to meet the enrollment target, recruitment was opened to individuals who participated in PD GENEration (NCT04057794), a PD genetic testing study led by the Parkinson’s Foundation [41,42].”
Self-citationWang, J., Ibrahim, V., Alcalay, R. N., Agin‐Liebes, J., NANCE, M. A., Beck, J. C., Caulfield, M. E., Naito, A., Galvelis, K. G., & Wills, A.-M. A. (2025) · medRxiv · doi:10.1101/2025.07.29.25332392
Self-citationTrichloroethylene and Parkinson Disease
Dorsey, E. R., & Tanner, C. M. (2025) · Neurology · doi:10.1212/wnl.0000000000214245
Antiepileptic Drugs and Parkinson's Disease: A Meta-Analysis of Existing Evidence
Akhmedullin, R., Kalinina, D., Kazhaparova, D., Sarría‐Santamera, A., Kyrgyzbay, G., & Kaiyrzhanov, R. B. (2025) · Epidemiology and Health Data Insights · doi:10.63946/ehdi/17420
Balck, A., Vollstedt, E., Westenberger, A., Lange, L. M., Trinh, J., Kasten, M., Lohmann, K., Brüggemann, N., Trenkwalder, C., Mollenhauer, B., et al. (2025) · medRxiv · doi:10.1101/2025.11.15.25339249
Self-citationSaminathan, A., Nagarthinam, I., Paramanandam, V., Venkatesan, V., & Koshy, T. (2025) · Egyptian Journal of Medical Human Genetics · doi:10.1186/s43042-025-00820-6
Proceedings of the 13th annual deep brain stimulation think tank: the evolving landscape
Fleeting, C. R., Moraud, E. M., Uǧurbil, K., Wang, D. D., Neumann, W., Kühn, A. A., Voon, V., Pikov, V., Welter, M., Fox, M., et al. (2026) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2026.1770451 · Cited by 1
“Larger cohorts, such as those from PDGeneration (Cook et al., 2024) and the Global Parkinson’s Genetic Program (GP2), although not specifically designed to evaluate DBS outcomes, could provide valuable insights into the relationship between genetic factors and DBS responses in PD.”
Self-citationGenetic landscape of Parkinson’s disease in the Personalized Parkinson Project cohortPreprint
Lüth, T., Klein, C., Helmich, R. C. G., Brüggemann, N., Hrir, S., Kuiperij, H. B., Gorgogietas, V. A., Fernandes, S. B. G., Prasuhn, J., May, P., et al. (2026) · medRxiv · doi:10.64898/2026.03.16.26348127
The GBA1 p. E427K (p. E388K ) Variant Is a Risk Factor for Synucleinopathies: A Meta‐Analysis
Chifamba, L. V., Parlar, S. C., Somerville, E. N., Liu, L., Yu, E., Asayesh, F., Ahmad, J., Teferra, M., Ruskey, J. A., Waters, C., et al. (2026) · Movement Disorders · doi:10.1002/mds.70367
Self-citationConnor‐Robson, N., Diviney, T., Alegre‐Abarrategui, J., Roberts, B. M., Brimblecombe, K. R., Bengoa‐Vergniory, N., Waters, H., Cioroch, M., Davies, B. L., Bila, K. O., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.25.727583
Multi-ancestry analysis of POLG variants in Parkinson’s diseasePreprint
Tay, Y. W., Elsayed, I., Yeow, D., James, M., Kung, P., Screven, L., Dilliott, A. A., Alcalay, R. N., Fang, Z., Tan, A. H., et al. (2026) · medRxiv · doi:10.64898/2026.06.07.26354811 · Cited by 1
Self-citationChinese herbal and natural compounds for Parkinson's disease: Myth or truth
Zhang, R., Chen, Y., Qian, Y., Zhu, C., Yang, J., & Zhang, J. (2026) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2026.122047 · Cited by 1
Lange, L. M., Cerquera‐Cleves, C., Tan, A. H., Lim, S., Okubadejo, N. U., Lin, C., Chen, P., Shin, J. H., Ahmad‐Annuar, A., Screven, L. A., et al. (2026) · medRxiv · doi:10.64898/2026.06.12.26354932
Self-citationMapping the Parkinson's pandemic: Unveiling and addressing the global burden
Shalash, A., Schuh, A. F. S., Salama, M., Noyce, A. J., Ha, U. N. L., Tan, L. C. S., & Tanner, C. M. (2026) · Journal of Parkinson s Disease · doi:10.1177/1877718x261459875 · Cited by 2
Parkinson’s disease associated with a mutation in the glucocerebrosidase gene
Sayfitdinkhuzhaev, Z. F., Жукова, Н. Г., Israilova, G. M., Zhukova, I. A., Masenko, A. Y., & Gaponova, O. V. (2026) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro202612606117 · Cited by 2
Bogers, J. S., Darweesh, S. K. L., Bloem, B. R., Hepp, D. H., van Asseldonk, T., van Laar, T., Vermeulen, R. C. H., & Peters, S. (2026) · BMJ Open · doi:10.1136/bmjopen-2026-120886 · Cited by 1
Vera, K., Gajic, I., Kusumanchi, P., Andaluz, A., Pena, G. D., Froelich, C. A., Higgins, E., Johnston, J., & Motevalian, S. P. (2026) · Biotechnology Progress · doi:10.1002/btpr.88542
Smeriglio, E., Imbesi, M., Xiao, J., Smeriglio, A., & Trombetta, D. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1924338
“ML may integrate these variants with age at onset, family history, motor and non-motor features, biomarkers, and progression patterns to identify clinically coherent subgroups (Cook et al., 2024).”
GCH1 genetic variation as a prognostic factor in Parkinson’s disease across populationsPreprint
Shin, J. H., Periñán, M. T., Jang, J. W., Screven, L., Lange, L. M., Klein, C., Shulman, J. M., Gan‐Or, Z., Shahkhali, M. G., Senkevich, K. A., et al. (2026) · medRxiv · doi:10.64898/2026.08.14.26359677
Self-citationGutierrez-Arratia, J. D., Awad, P. S., Schuh, A. F. S., & Cornejo‐Olivas, M. (2026) · Journal of Parkinson s Disease · doi:10.1177/1877718x261478730
“56 The initiative demonstrates how global research synergy can integrate variant discovery with patient engagement and local capacity building.”
LRRK2: Molecular Mechanisms in Parkinson’s Disease
Arias-Carrión, Ó., Guerra‐Crespo, M., Ortuño‐Sahagún, D., & Ortega‐Robles, E. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177606
Milardi, D., Han, J., Lee, H. J., Ding, F., Miller, Y., Faller, P., Bush, A. I., Crouch, P. J., Finkelstein, D. I., Double, K. L., et al. (2026) · Chemical Reviews · doi:10.1021/acs.chemrev.5c00420
Emerging therapies expected to make a difference in Parkinson's disease management
An, Y. A., & Kalia, L. V. (2026) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2026.108962
Genomic Landscape of Early-Onset and Familial Latin American Parkinson’s PatientsPreprint
Waldo, E., Chaparro-Solano, H. M., Isayan, M., Leal, T. P., Duarte-Zambrano, F., Inca‐Martinez, M., Ramchandra, J., Paz, M., Makarious, M. B., Hernández, C. F., et al. (2026) · medRxiv · doi:10.64898/2026.09.16.26359514
Self-citation
Metadata
- Authors
- Cook, L., Verbrugge, J., Schwantes-An, T.-H., Schulze, J., Foroud, T., Hall, A., Marder, K. S., Mata, I. F., Mencacci, N. E., Nance, M. A., Schwarzschild, M. A., Simuni, T., Bressman, S., Wills, A.-M., Fernandez, H. H., Litvan, I., Lyons, K. E., Shill, H. A., Singer, C., Tropea, T. F., Vanegas Arroyave, N., Carbonell, J., Cruz Vicioso, R., Katus, L., Quinn, J. F., Hodges, P. D., Meng, Y., Strom, S. P., Blauwendraat, C., Lohmann, K., Casaceli, C., Rao, S. C., Ghosh Galvelis, K., Naito, A., Beck, J. C., & Alcalay, R. N.
- Affiliations
- Indiana University School of Medicine (US)
- Parkinson's Foundation (US)
- Columbia University Irving Medical Center (US)
- Cleveland Clinic (US)
- Northwestern University (US)
- Struthers Parkinson’s Center, Golden Valley , MN 55427 , USA
- Massachusetts General Hospital (US)
- Icahn School of Medicine at Mount Sinai (US)
- University of California San Diego (US)
- University of Kansas Medical Center (US)
- Barrow Neurological Institute (US)
- University of Miami (US)
- University of Pennsylvania (US)
- Department of Neurology, Baylor College of Medicine , Houston, TX 77030 , USA
- Centro Cardioneuro Oftalmológico y Trasplante , Santo Domingo 10306, República Dominicana
- Medicina Interna, Clínica Unión Médica del Norte , Santiago de los Caballeros 51000, República Dominicana
- Oregon Health & Science University (US)
- Temple Lung Center (US)
- Illumina (United States) (US)
- National Institutes of Health (US)
- University of Lübeck (DE)
- University of Rochester Medicine (US)
- Parkinson’s Foundation , NewYork, NY 10018 , USA
- Corresponding author
- Alcalay, Roy N
- ORCID
- Cook, Lola
- Verbrugge, Jennifer
- Schwantes-An, Tae-Hwi
- Schulze, Jeanine
- Foroud, Tatiana
- Marder, Karen S
- Mata, Ignacio F
- Mencacci, Niccolò E
- Nance, Martha A
- Schwarzschild, Michael A
- Simuni, Tanya
- Bressman, Susan
- Wills, Anne-Marie
- Fernandez, Hubert H
- Litvan, Irene
- Lyons, Kelly E
- Shill, Holly A
- Singer, Carlos
- Tropea, Thomas F
- Katus, Linn
- Quinn, Joseph F
- Hodges, Priscila D
- Meng, Yan
- Strom, Samuel P
- Blauwendraat, Cornelis
- Lohmann, Katja
- Rao, Shilpa C
- Naito, Anna
- Beck, James C
- Alcalay, Roy N
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2024-07-30
- Volume
- 147
- Issue
- 8
- Pages
- 2668-2679
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC11292896
- OpenAlex
- W4401158013
- Cited by
- 108
- References
- 28
- Citations by year
- 2026: 44 · 2025: 55 · 2024: 9
- FWCI
- 28.90
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Brain (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- IUScholarWorks (Indiana University) (submittedVersion, cc-by)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- Parkinson’s Foundation
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Keywords
- Parkinson's disease, genetic testing, genetic counseling, LRRK2, GBA1, Parkin, SNCA, PINK1, DJ-1, VPS35, genetic risk variants, genetic aetiology, genetic ancestry, early-onset Parkinson's disease, North America, Puerto Rico, Dominican Republic
- MeSH terms
- Leucine-Rich Repeat Serine-Threonine Protein Kinase-2, Protein Deglycase DJ-1, PTEN-Induced Putative Kinase, Adult, Aged, Canada, Female, Genetic Counseling, Genetic Testing, Glucosylceramidase, Humans, Male, Middle Aged, North America, Parkinson Disease, Protein Kinases, United States, Genetic Variation, Genetic Predisposition to Disease, Disclosure, Vesicular Transport Proteins, Ubiquitin-Protein Ligases, alpha-Synuclein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.